Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Abstract Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with...

Full description

Bibliographic Details
Main Authors: Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P. Vassilakopoulos, Priyanka Samal, Matthew Ku, Xiwen Ma, Kelly Corona, Kamal Chamoun, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Miguel Canales
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Hematology & Oncology
Subjects:
Selinexor
Exportin-1
SINE compounds
DLBCL
Online Access:https://doi.org/10.1186/s13045-021-01122-1

Internet

https://doi.org/10.1186/s13045-021-01122-1

Similar Items